Sarraf Pasha
CIK: 0002059447
Sarraf Pasha's purchase track record
Sarraf Pasha has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 12/30/2025 | CUE | $100K | -23.8% | +248.3% | +8.8% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| CUE | ▲ Buy | Grant | 21,800 | $0 | 7/9/2026 | View on chart |
| CUE | ▲ Buy | Open Market | 4,229 | $1K | 12/30/2025 | View on chart |
| CUE | ▲ Buy | Open Market | 77,148 | $23K | 12/30/2025 | View on chart |
| CUE | ▲ Buy | Open Market | 86,947 | $28K | 12/30/2025 | View on chart |
| CUE | ▲ Buy | Open Market | 78,116 | $24K | 12/30/2025 | View on chart |
| CUE | ▲ Buy | Open Market | 77,417 | $23K | 12/30/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Cue Biopharma CUE-221 Meets Phase II Goals for Hives
Cue Biopharma reported that its drug CUE-221 met Phase II goals in chronic spontaneous urticaria, showing durable responses. The news highlights potential for longer-lasting relief compared to current treatments. Despite positive results, the stock has experienced an unwarranted slide, though it remains well below the average analyst target.
Cue Biopharma CUE-221 Meets Phase II Goals for Hives. Cue Biopharma reported that its drug CUE-221 met Phase II goals in chronic spontaneous urticaria, showing durable responses. The news highlights potential for longer-lasting relief compared to current treatments. Despite positive results, the stock has experienced an unwarranted slide, though it remains well below the average analyst target.